Skip to content

Company information lookup

NEUREN PHARMACEUTICALS LIMITED (NEU)

Biopharmaceutical company with a focus on neurological conditions.

On this page you will find:

Delayed share price
Company announcements
Price history chart
Exchange Traded Options
ASX-Listed Emblem Company details
Closing prices
Dividends
Warrants & Structured Products
ASX CFDs

Delayed share price

Prices are delayed by 20 minutes unless stated otherwise in the Conditions. Retrieving any price indicates your acceptance of the Conditions.

Code Last % Chg Bid Offer Open High Low Vol
NEU 0.096 1.05% 0.096 0.100 0.096 0.105 0.096 6,780,844

NEUREN PHARMACEUTICALS LIMITED details

Please note: ASX relies on third parties to provide the information contained in the company details table, and therefore is unable to assume any responsibility for the accuracy or timeliness of the information.

Issuer Code NEU
Securities
Official Listing Date 3 February, 2005
GICS Industry Group Pharmaceuticals, Biotechnology & Life Sciences
Exempt Foreign? No
Internet Address http://www.neurenpharma.com
Registered Office Address At the offices of Lowndes Jordan, Level 15, PWC Tower, 188 Quay Street, AUCKLAND, ., NEW ZEALAND, 1141
Head Office Telephone +61 3 9092 0480
Head Office Fax +64 9 361 7981
Share Registry LINK MARKET SERVICES LIMITED
LEVEL 1, 333 COLLINS STREET, MELBOURNE, VIC, AUSTRALIA, 3000
Share Registry Telephone 1300 554 474
Directors / Senior Management
Dr Richard Treagus (Executive Chairman)
Mr Larry Glass (Executive Director)
Mr Bruce Hancox (Non Exec. Director)
Mr Trevor Scott (Non Exec. Director)
Mr Jon Pilcher (CFO)
Company Secretary Mr Jon Pilcher
Principal Activities Biopharmaceutical company with a focus on neurological conditions.

NEUREN PHARMACEUTICALS LIMITED announcements

How are company announcements published on www.asx.com.au?

Date Price
sens.
Headline Pages PDF
22/07/2014   Appendix 3B 13 PDF
18/07/2014 asterix Appendix 4C - quarterly 5 PDF
17/07/2014 asterix US$3m increase to US Army grant and INTREPID outlook update 2 PDF
10/07/2014 asterix Neuren receives ethics approval to start Concussion trial 2 PDF
26/06/2014 asterix Neuren completes enrolment in Phase 2 trial in Rett Syndrome 2 PDF
25/06/2014   Appendix 3B 13 PDF
23/06/2014   Neuren appoints CMC expert to leadership team 1 PDF
04/06/2014 asterix Neuren receives new US patent for NNZ-2591 2 PDF
03/06/2014   Appendix 3B 14 PDF
03/06/2014   Appendix 3B 14 PDF

> search for past company announcements

Viewing Market Announcements:
Users of Adobe Acrobat Reader version 6.0.0 may have difficulty accessing PDF announcements. Symptoms include slow downloads, blank documents, and small white boxes appearing in the PDF. We recommend you download the latest version of the free Adobe Acrobat Reader. To check which version you have, open Adobe Acrobat Reader, click on 'Help', then click 'About Adobe Reader 6.0'.

Closing prices

Closing prices are displayed for the last 5 days on which the security traded on ASX within the last 6 months.

Date Last % Change High Low Vol *
22 Jul 2014 0.095 2.15% 0.102 0.094 10,055,955
21 Jul 2014 0.093 4.49% 0.096 0.090 3,349,648
18 Jul 2014 0.089 0% 0.091 0.087 1,171,633
17 Jul 2014 0.089 -2.2% 0.096 0.089 3,974,944
16 Jul 2014 0.091 0% 0.091 0.088 1,391,292

* Volume of shares shown represents only those shares traded on ASX.

NEUREN PHARMACEUTICALS LIMITED price history chart

* More charting options are available.

Dividends

How are dividends released on www.asx.com.au?

No dividends have been found for the security NEU. This is likely to be because a dividend has not been announced to the ASX by this company during the specified timeframe or a dividend has been announced but is not yet available on this website.

Exchange Traded Options

No Exchange Traded Options are available over the security NEU

Warrants & Structured Products

No warrants & Structured Products are available over the security NEU

ASX CFDs

No Contracts For Differences are available over the security NEU